CollPlant Biotechnologies Ltd.
CLGNNASDAQHealthcare● Active
$0.37
$-0.00(-0.27%)
Market Cap$4522010
P/E Ratio—
52W High$3.232
52W Low$0.271
CollPlant Biotechnologies Ltd. (CLGN) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CLGN · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 29, 2026EPS Actual
-$0.23
Est. -$0.24 · +3.1%
Revenue
$0.00B
Est. $0.00B · -84.1%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 29, 2026
After Market Close
▲ Beat EPS▼ Miss Revenue✓ 1-Quarter EPS Beat Streak
CLGN reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 20, 2026 | -$0.24 | — | — | — | $0.00B | — |
| ▲ Q2 FY2026 | May 29, 2026 | -$0.24 | -$0.23 | +3.1% | $0.00B | $0.00B | -84.1% |
| ▼ Q1 FY2026 | Mar 26, 2026 | -$0.30 | -$0.67 | -125.1% | $0.00B | $0.00B | -97.1% |
| ▼ Q4 FY2025 | Nov 26, 2025 | $0.38 | -$0.27 | -171.1% | $0.00B | $0.01B | -98.9% |
| ▼ Q3 FY2025 | Aug 20, 2025 | -$0.10 | -$0.28 | -180.0% | $0.00B | $0.02B | -98.9% |
| ▲ Q2 FY2025 | May 28, 2025 | -$0.37 | -$0.13 | +64.9% | $0.00B | $0.01B | -76.9% |
| ▲ Q1 FY2025 | Mar 26, 2025 | -$0.42 | -$0.34 | +19.1% | $0.00B | $0.00B | +64.0% |
| ▼ Q4 FY2024 | Nov 27, 2024 | -$0.28 | -$0.38 | -35.7% | $0.00B | $0.00B | -98.9% |
Q3 FY2026
Aug 20, 2026
EPS Actual
—
EPS Est.
-$0.24
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 29, 2026Beat
EPS Actual
-$0.23
EPS Est.
-$0.24
EPS Surpr.
+3.1%
Revenue
$0.00B
Q1 FY2026
Mar 26, 2026Miss
EPS Actual
-$0.67
EPS Est.
-$0.30
EPS Surpr.
-125.1%
Revenue
$0.00B
Q4 FY2025
Nov 26, 2025Miss
EPS Actual
-$0.27
EPS Est.
$0.38
EPS Surpr.
-171.1%
Revenue
$0.00B
Q3 FY2025
Aug 20, 2025Miss
EPS Actual
-$0.28
EPS Est.
-$0.10
EPS Surpr.
-180.0%
Revenue
$0.00B
Q2 FY2025
May 28, 2025Beat
EPS Actual
-$0.13
EPS Est.
-$0.37
EPS Surpr.
+64.9%
Revenue
$0.00B
Q1 FY2025
Mar 26, 2025Beat
EPS Actual
-$0.34
EPS Est.
-$0.42
EPS Surpr.
+19.1%
Revenue
$0.00B
Q4 FY2024
Nov 27, 2024Miss
EPS Actual
-$0.38
EPS Est.
-$0.28
EPS Surpr.
-35.7%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.04 | $-0.04 | $-0.04 | 1 |
| Q3 FY2028 | $-0.04 | $-0.04 | $-0.04 | 1 |
| Q2 FY2028 | $-0.04 | $-0.04 | $-0.04 | 1 |
| Q1 FY2028 | $-0.04 | $-0.04 | $-0.04 | 1 |
| Q4 FY2027 | $-0.04 | $-0.04 | $-0.04 | 1 |
| Q3 FY2027 | $-0.05 | $-0.05 | $-0.05 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 29, 2026 | +3.1% | $0.41 | $0.40 | -0.74% |
| ▼ Q1 FY2026 | Mar 26, 2026 | -125.1% | $0.75 | $0.66 | -12.02% |
| ▼ Q4 FY2025 | Nov 26, 2025 | -171.1% | $2.24 | $2.23 | -0.45% |
| ▼ Q3 FY2025 | Aug 20, 2025 | -180.0% | $2.47 | $1.97 | -20.24% |
| ▲ Q2 FY2025 | May 28, 2025 | +64.9% | $1.93 | $3.40 | +76.17% |
| ▲ Q1 FY2025 | Mar 26, 2025 | +19.1% | $2.80 | $2.71 | -3.21% |
| ▼ Q4 FY2024 | Nov 27, 2024 | -35.7% | $4.26 | $4.25 | -0.23% |
| ▼ Q3 FY2024 | Aug 20, 2024 | -5.7% | $4.91 | $4.85 | -1.22% |
Q2 FY2026-0.74%
Report Date
May 29, 2026
EPS Beat/Miss
+3.1%
Price Before
$0.41
Price After
$0.40
Q1 FY2026-12.02%
Report Date
Mar 26, 2026
EPS Beat/Miss
-125.1%
Price Before
$0.75
Price After
$0.66
Q4 FY2025-0.45%
Report Date
Nov 26, 2025
EPS Beat/Miss
-171.1%
Price Before
$2.24
Price After
$2.23
Q3 FY2025-20.24%
Report Date
Aug 20, 2025
EPS Beat/Miss
-180.0%
Price Before
$2.47
Price After
$1.97
Q2 FY2025+76.17%
Report Date
May 28, 2025
EPS Beat/Miss
+64.9%
Price Before
$1.93
Price After
$3.40
Q1 FY2025-3.21%
Report Date
Mar 26, 2025
EPS Beat/Miss
+19.1%
Price Before
$2.80
Price After
$2.71
Q4 FY2024-0.23%
Report Date
Nov 27, 2024
EPS Beat/Miss
-35.7%
Price Before
$4.26
Price After
$4.25
Q3 FY2024-1.22%
Report Date
Aug 20, 2024
EPS Beat/Miss
-5.7%
Price Before
$4.91
Price After
$4.85
Avg Beat Reaction+24.07%
Avg Miss Reaction-6.83%
Beat Rate3 / 8 quarters
Largest Move+76.17% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CLGN ends December
CollPlant Biotechnologies Ltd. (CLGN) most recently reported earnings on May 29, 2026 for Q2 FY2026, posting EPS of $-0.23 — beating the analyst consensus of $-0.24 by +3.1%. The next CLGN earnings date is expected around September 1, 2026.
Each quarter, investors track CLGN earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CLGN revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CLGN's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CLGN earnings · 5 questionsCollPlant Biotechnologies Ltd.'s next earnings report is expected around September 1, 2026. CLGN typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CLGN historically reports after market close (AMC).
CLGN earnings datewhen is CLGN earningsCLGN next earnings datewhen does CLGN report earningsCLGN earnings calendar
▸ Source: FMP · CollPlant Biotechnologies Ltd. SEC filings · US GAAP · CollPlant Biotechnologies Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026